Low uptake of HCV treatment in England will lead to substantial disease burden by 2035
Even moderate drinking increases risk of advanced liver fibrosis for people with HIV and HCV co-infection
Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation
Sustained response to treatment reduces fatigue in hepatitis C patients
Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4
Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence
Sofosbuvir for hepatitis C works well despite multiple negative predictive factors
Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6
